Bufuralol Hydrochloride: A Benchmark β-Adrenergic Receptor Antagonist for Cardiovascular Pharmacology Research

Executive Summary: Bufuralol hydrochloride (CAS 60398-91-6) is a crystalline, non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity, used widely in cardiovascular pharmacology research (APExBIO). Its capacity to induce tachycardia in catecholamine-depleted animal models provides a distinct experimental advantage for probing beta-adrenoceptor signaling pathways (Szekeres 1977, DOI). Membrane-stabilizing effects have been confirmed in vitro, supporting its utility as a reference compound (DOI). Bufuralol hydrochloride demonstrates stable solubility parameters in common laboratory solvents, with optimal storage at -20°C. Integration with hiPSC-derived intestinal organoid systems enables advanced pharmacokinetic and β-adrenergic modulation studies (DOI).

Biological Rationale

The β-adrenergic receptor system regulates critical cardiovascular functions, including heart rate, contractility, and vascular tone (DOI). Non-selective β-adrenergic antagonists, such as bufuralol hydrochloride, are essential for dissecting these pathways in both basic and translational research. Bufuralol hydrochloride exhibits partial intrinsic sympathomimetic activity, enabling nuanced studies of receptor function, signal transduction, and drug response under varied physiological and pathological conditions (APExBIO).

Recent advances in human pluripotent stem cell-derived intestinal organoid models have transformed the landscape for in vitro pharmacokinetic and pharmacodynamic studies (DOI). These systems recapitulate drug absorption, metabolism, and excretion, providing more predictive data than traditional animal or cancer-derived cell lines.

Mechanism of Action of Bufuralol hydrochloride

Bufuralol hydrochloride is a non-selective β-adrenergic receptor blocker, antagonizing both β₁ and β₂ adrenoceptors. It competes with endogenous catecholamines for receptor binding sites, inhibiting downstream cyclic AMP generation and subsequent protein kinase A activation (APExBIO). This leads to reduced heart rate, contractility, and overall sympathetic output.

Unlike purely antagonistic agents, bufuralol exhibits partial intrinsic sympathomimetic activity, which allows it to induce limited receptor activation even while occupying the receptor. In animal models with depleted catecholamine stores, bufuralol can elicit tachycardia, distinguishing it from classic antagonists (DOI). In vitro, bufuralol demonstrates membrane-stabilizing effects, attributed to its interaction with lipid bilayers and potential sodium channel modulation.

Evidence & Benchmarks

• Bufuralol hydrochloride inhibits exercise-induced heart rate elevation in humans with a duration of action comparable to propranolol (Szekeres 1977, DOI).
• Partial intrinsic sympathomimetic activity is evidenced by tachycardia induction in catecholamine-depleted animal models (Szekeres 1977, DOI).
• Bufuralol hydrochloride displays in vitro membrane-stabilizing action, impacting cardiac myocyte excitability (Szekeres 1977, DOI).
• The compound is soluble up to 15 mg/ml in ethanol, 10 mg/ml in DMSO, and 15 mg/ml in dimethyl formamide at laboratory temperatures (APExBIO).
• hiPSC-derived intestinal organoids provide a human-relevant platform for pharmacokinetics and β-adrenergic modulation studies using bufuralol hydrochloride (Saito et al. 2025, DOI).

For a more nuanced perspective on integrating bufuralol hydrochloride in organoid systems, see Integrating Bufuralol Hydrochloride with Next-Gen Organoid Models, which details strategic advances in translational workflows. This article extends the mechanistic focus by providing validated solubility and storage parameters for experimental reproducibility.

Applications, Limits & Misconceptions

Bufuralol hydrochloride is a reference compound for:

• β-adrenergic modulation studies in cardiac and smooth muscle tissue.
• Pharmacokinetic profiling in hiPSC-derived intestinal organoids (DOI).
• Comparative studies of membrane-stabilizing agents in vitro.
• Modeling partial agonism versus full antagonism in beta-adrenoceptor signaling pathways.

Bufuralol hydrochloride’s long-acting inhibition of exercise-induced tachycardia is especially useful for chronic β-adrenergic blockade studies (APExBIO).

Common Pitfalls or Misconceptions

• Bufuralol hydrochloride is not a selective β₁- or β₂-antagonist; it blocks both subtypes equally.
• Its partial intrinsic sympathomimetic activity may confound studies requiring pure receptor blockade.
• Membrane-stabilizing effects can impact electrophysiological assays beyond β-adrenergic modulation.
• Solutions are chemically unstable over time; prepare fresh prior to use and avoid long-term storage.
• Animal models may not fully predict human pharmacokinetics; hiPSC-derived organoids are recommended for translational studies (DOI).

To contrast, Redefining Cardiovascular Pharmacology provides a broader review of β-adrenergic blockade, while this article delivers product-specific physicochemical and workflow integration data.

Workflow Integration & Parameters

For optimal results, dissolve bufuralol hydrochloride (C16H23NO2·HCl, MW 297.8) in ethanol (up to 15 mg/ml), DMSO (10 mg/ml), or dimethyl formamide (15 mg/ml). Use freshly prepared solutions. Store stock at -20°C and avoid repeated freeze-thaw cycles (APExBIO).

In hiPSC-derived intestinal organoid workflows, bufuralol hydrochloride can be used to probe transporter function, metabolic capacity (notably CYP3A4), and β-adrenergic signaling in a human-relevant context (DOI). For advanced guidance on integrating this compound into multi-parametric organoid assays, Bufuralol Hydrochloride and the Evolution of Cardiovascular Pharmacology demonstrates the translational step from in vitro validation to disease modeling; this work is complemented here with specific solvent compatibility and storage data.

For broader applications in cardiovascular disease research, bufuralol hydrochloride supports studies of partial agonism, arrhythmogenesis, and membrane stabilization in both traditional and next-generation human-derived model systems.

Conclusion & Outlook

Bufuralol hydrochloride, supplied by APExBIO, remains a reference tool for β-adrenergic modulation studies in cardiovascular pharmacology. Its unique profile—combining non-selective receptor antagonism, partial intrinsic sympathomimetic activity, and membrane-stabilizing properties—supports diverse experimental designs. Integration with hiPSC-derived organoid platforms propels it into the forefront of translational pharmacokinetics and disease modeling. As in vitro systems become increasingly human-relevant, bufuralol hydrochloride's robust data backbone ensures reproducibility and comparability across studies. For further reading, Bufuralol Hydrochloride in Advanced β-Adrenergic Pharmacology highlights emerging applications, while this article provides actionable details for bench scientists and translational researchers alike.